MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia [PDF]
Leukemia, 2023 Resistance to tyrosine kinase inhibitors (TKIs) remains a clinical challenge in Ph-positive variants of chronic myeloid leukemia. We provide mechanistic insights into a previously undisclosed MEK1/2/BCR::ABL1/BCR/ABL1-driven signaling loop that may ...
Abeltino M. +19 more
core +5 more sources
Inflammation Promotes Oxidative and Nitrosative Stress in Chronic Myelogenous Leukemia [PDF]
Biomolecules, 2022 Chronic inflammation is characterized by the production of reactive oxygen species (ROS), reactive nitrogen species, and inflammatory cytokines in myeloproliferative neoplasms (MPNs).
Bogdanović, Andrija +10 more
core +2 more sources
DETECTION OF BCR-ABL PROTEIN IN CHRONIC MYELOID LEUKEMIA PATIENTS USING IMMUNOCYTOCHEMISTRY
The Iraqi Journal of Medical Sciences, 2016 Background: Chronic Myeloid leukemia (CML) is a myeloproliferetive disorder associated with chromosomal abnormality, Philadelphia chromosome (Ph), in more than 95% of CML patients. The resulting BCR-ABL fused gene is markers for this type of leukemia. In
Maysaa Abdul Razaq Dhahi +2 more
doaj +6 more sources
Diagnosed hematological malignancies in Bangladesh - a retrospective analysis of over 5000 cases from 10 specialized hospitals [PDF]
, 2014 Background The global burden from cancer is rising, especially as low-income countries like Bangladesh observe rapid aging. So far, there are no comprehensive descriptions reporting diagnosed cancer group that include hematological malignancies in ...
Abedin, AKM +20 more
core +7 more sources
Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia [PDF]
, 2014 Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the BCR/ABL1 oncogene. Although mechanisms of BCR/ABL1-induced transformation are well-defined, little is known about effector-molecules contributing to malignant expansion and ...
Bilban, Martin +15 more
core +1 more source
The effect of imatinib mesylate on the proliferation, invasive ability, and radiosensitivity of retinoblastoma cell lines [PDF]
, 2012 Purpose Our aim was to evaluate the potential effect of imatinib mesylate (IM), a small molecule that specifically inhibits the tyrosine quinase receptors, on the proliferation and invasive abilities of two human retinoblastoma (Rb) cell lines ...
Antecka, E. +5 more
core +2 more sources
Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology. [PDF]
, 2016 Circulating tumor cells (CTCs) are emerging as rare but clinically significant non-invasive cellular biomarkers for cancer patient prognosis, treatment selection, and treatment monitoring.
Che, James +15 more
core +2 more sources
Pre-B-cell acute lymphoblastic leukemia with bulk extramedullary disease and chromosome 22 (EWSR1) rearrangement masquerading as Ewing sarcoma [PDF]
, 2010 We report a 2-year-old female with a subcutaneous tumor who was initially misdiagnosed as suffering from Ewing sarcoma with a positive EWSR1 rearrangement and EWS/FLI1 transcript.
Jakovljević, Gordana +6 more
core +1 more source
Brazilian Journal of Medical and Biological Research, 2013 Imatinib mesylate (IM) is used to treat chronic myeloid leukemia (CML) because it selectively inhibits tyrosine kinase, which is a hallmark of CML oncogenesis.
P.B. Soares +5 more
doaj +1 more source
Clinical relevance of P-glycoprotein expression in haematological malignancies [PDF]
, 1994 Although, generally speaking, haematological malignancies are chemotherapy-responsive tumours and high remission induction rates are obtained, disease-related death is the rule rather than the exception.
Nooter, K. (Kees) +1 more
core +2 more sources